See Asa at Microbiome & Probiotic R&D & Business Collaboration Forum - La Jolla, California 10/13/2025
August 27, 2025 By: Asa Waldstein

Essential Oil Inhaler Makes Alzheimer’s Claims

Takeaway -

Top 10 weirdest and cringiest warning letters

Top 10 weirdest and cringiest warning letters I’ve ever seen. FDA issued a warning letter to a company selling an essential oil-looking nasal diffuser for Alzheimer’s treatment, dementia, and other conditions. I can’t make this stuff up!

From warning letter: “Reverses dementia, boosts brain cognition, and prevents Alzheimer’s disease.”

This product appears to contain lavender, monk fruit, rosemary, and mint, and the company suggests inhaling it through the nose several times daily to “prevent dementia.” It also claims to be “FDA approved” and features what appears to be a fake approval letter on its website. 

From warning letter: “Your website https://www.alzclipp.com/ includes an image of an FDA logo with the words “FDA approved” below it. The website also includes an image of a certificate with an FDA logo and the headline, “FDA Approves AlzClipp: A Groundbreaking Brain Health Innovation” next to the image of “AlzClipp.”

This entire website just felt icky, so I ran a Google image search on one of the testimonial images, and it revealed several of the exact images on different medical sites. This leads me to think this is a stock image used to fill in other websites. This means that the testimonials may not be compliant, which is the epitome of deceptive marketing.

This product feels like an experiment in pushing ethical boundaries to their limits. Wow, just wow. I suggest everyone check out the warning letter. 

Disclaimer: The educational information provided here is for informational purposes only. Contact an attorney for specific legal advice. Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Written by

Asa Waldstein
Asa Waldstein
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Cannabis Committee, helping shape policy and industry best practices
Read all my posts
«